SLS, IBRX, IOVA End October In Red: Merck And AstraZeneca Earnings Put Cancer Bets And Buyout Hopes In Focus
Article excerpt
Sellas Life Sciences (SLS), ImmunityBio (IBRX) and Iovance Biotherapeutics (IOVA) ended October lower, while earnings updates from Merck (MRK) and AstraZeneca (AZN) put cancer vaccines, emerging competition and retail buyout hopes in focus. IOVA plunged 43% in October, while SLS shed 21% and IBRX fell 12%, all sharply underperforming the SPDR S&P Biotech ETF (XBI), which slipped 1.1%. Merck And AstraZeneca Map Their Cancer Push Merck’s earnings call offered cancer-vaccine optimism alongside signs of growing competition in lung and bladder cancer. While discussing its Moderna-partnered melanoma vaccine, research chief Dean Li said: “These results, building on the body of evidence from the phase IIb study, strengthen our confidence in the curative potential of intismeran when given in combination with KEYTRUDA.” Merck also highlighted a Keytruda-ADC combination that improved progression-free survival over Keytruda plus chemotherapy in a first-line lung-cancer study, and Phase 2 vaccine trials in bladder cancer. These programs point to potential future competition in markets targeted by Iovance and ImmunityBio. On AstraZeneca’s call, CEO Pascal Soriot highlighted its Summit Therapeutics partnership combining antibody-drug conjugates, or ADCs, with Ivonescimab. “We believe ADCs will become the backbone of treatment across tumor types, and this partnership gives flexibility to...
Keep reading with a free account
The rest of this article, and every signal for AstraZeneca, is in your free account.
Extracted from this sentence
AstraZeneca is also investing in cell therapies and developing cancer vaccines internally.
